Ivermectin has shown promise against Covid-19 in a clinical trial and patients receiving a five-day course of ivermectin have shown an early viral clearance and improvements of blood biomarkers compared with other two groups.

Paul-Ehrlich-Institut (PEI), Germany's Federal Institute for Vaccines and Biomedicines, has approved the third clinical trial of a potential COVID-19 vaccine.